Reuters logo
Aerie Pharma's eye drug succeeds in mid-stage trial
June 25, 2014 / 10:30 AM / 3 years ago

Aerie Pharma's eye drug succeeds in mid-stage trial

June 25 (Reuters) - Drug developer Aerie Pharmaceuticals Inc said its once-daily eye treatment was shown to be superior to each of its two components in a mid-stage trial.

The drug, Roclatan, is a combination of Aerie’s other eye drug Rhopressa and a glaucoma medication called latanoprost. The combination was being tested in glaucoma patients. (Reporting By Amrutha Penumudi; Editing by Don Sebastian)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below